| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rani Therapeutics Holdings, Inc.$0.69
+0 (+0.24%)
D 33Pipeline Score Overvalued Biotech · Commercial
Market Cap
132.45 M
EPS
-0.41
P/E Ratio
-
Value Trade
614.03 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.71 M
R&D Expenses
5.16 M
Operating CF
-6.50 M
Total Assets
51.88 M
Total Liabilities
16.34 M
Equity
28.41 M
D/E Ratio
12,345
-3.6 %
Week
10.63 %
1 Month
-18.94 %
3 Month
-28.67 %
6 Month
-90.5 %
5 Year
-90.5 %
All Time
Cash Data
Cash Position
51.88 M
Monthly Burn
2.17 M
Runway
22.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
798.35 K
52 Week Range
0.39 - 3.87
% held by Insiders
18.93 %
% held by Institutions
25.18 %
Enterprise Value
99.92 M
Total Shares
99.85 M
Short %
11.86 %
Float Shares
76.58 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rani Therapeutics Holdings, Inc.
171Total events
4Upcoming
25Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 4
Event history 167
Jul 9, 2026
▲Partnership / LicenseCorporate
Rani and PegBio collaboration to explore oral delivery of PegBio's obesity molecules
obesity and metabolic diseasesource ↗
Jun 29, 2026
May 26, 2026
▼Equity OfferingCorporate
Pricing of $20.0 million registered direct offering of Class A common stock and pre-funded warrants
May 19, 2026
◆Oral PresentationPresentation
Rani Therapeutics management to present at H.C. Wainwright Annual BioConnect Investor Conference
May 15, 2026
Apr 9, 2026
Mar 26, 2026
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and business update
Mar 26, 2026
▲Partnership / LicenseCorporate
Up to $1.085 billion collaboration with Chugai Pharmaceutical Co.
Mar 26, 2026
Mar 26, 2026
●Preclinical PoCsemaglutidePreclinical
Preclinical data demonstrating successful oral delivery of semaglutide via RaniPill
Drug Pipeline Intelligence
D33
Pipeline Score $17M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.4x
rNPV / MCap Top 41%
Micro Cap (rank 538 of 911)
Percentile RankRani Therapeutics Holdings, Inc. faces pipeline headwinds (33/100), with $533M risk-adjusted pipeline value, led by PG-102 in Obesity (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PG-102 Small molecule | Obesity | Phase 1 | NCT06891287 | 14% | $463M | NOT YET_RECRUITING | 60 | AVERAGE | F (19) | Mar 1, 2026 | LOW_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RT-114 | obesity | Phase 1 | 2024-10-17 | weight loss transenteric: 9.7 ± 2.5 %; weight loss SC: 6.9 ± 2.1 %; relative bioavailability: 80% Read More | Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist Read More | |
RT-114 | obesity | Phase 1 | 2024-10-17 | weight loss transenteric: 9.7 ± 2.5 %; weight loss SC: 6.9 ± 2.1 %; relative bioavailability: 80% Read More | Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist Read More | |
RT-114 | obesity | Phase 1 | 2024-10-17 | weight loss transenteric: 9.7 ± 2.5 %; weight loss SC: 6.9 ± 2.1 %; relative bioavailability: 80% Read More | Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RANI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RANI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RANI▲ +0.2%today
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
Rani Therapeutics has announced a collaboration with PegBio to develop oral delivery systems for PegBio's obesity and metabolic disease candidates using the RaniPill® platform. This partnership aims to enhance Rani's existing obesity pipeline by adding multiple new candidates with diverse mechanisms of action. The collaboration reflects Rani's strategy to broaden its offerings in the obesity market.
Read more →RANIRani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Rani Therapeutics has appointed Nicholas Maestas as its new Chief Financial Officer, effective immediately. Maestas brings over a decade of financial leadership experience in the biotechnology sector, previously serving as CFO at Tempest Therapeutics. His appointment follows the departure of Svai Sanford, who led the company through a transitional period. Rani aims to enhance its oral delivery platform for biologics under Maestas' financial stewardship.
Read more →RANI▼ -12.1%on this news
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
Rani Therapeutics Holdings, Inc. has announced a registered direct offering of Class A common stock, aiming to raise approximately $20 million. The offering, priced at $1.07 per share, involves the sale of over 12 million shares and pre-funded warrants. The transaction is expected to close on May 27, 2026, pending customary conditions.
Read more →RANIRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Rani Therapeutics reported its first quarter 2026 financial results, highlighting advancements in the Phase 1 study of RT-114 for obesity. The company appointed new strategic leaders, including Jesper Høiland and Dr. Sara Kenkare-Mitra, to enhance its pipeline focus. Despite a net loss of $8 million, Rani's financial position remains strong, with sufficient cash to support operations into late 2027.
Read more →RANIRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference 2026
Rani Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Talat Imran and CFO Svai Sanford will present in a fireside chat format. The conference aims to showcase Rani's advancements in oral delivery technologies for biologics. A live webcast will be available for interested parties.
Read more →RANIRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rani Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with CEO Talat Imran and CFO Svai Sanford. The conference aims to showcase Rani's innovative oral delivery technology for biologics. Interested parties can access the live webcast through the company's website.
Read more →RANI▼ -6.1%on this news
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Rani Therapeutics has appointed Dr. Sara Kenkare-Mitra as a Strategic Advisor to enhance its platform and clinical strategy. With nearly 30 years of experience in drug discovery and development, she will guide the company in prioritizing programs and aligning development plans with regulatory considerations. Her expertise is expected to drive clinical success and long-term value creation for Rani.
Read more →RANI▼ -24.9%on this news
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
Rani Therapeutics reported strong financial results for Q4 and full year 2025, highlighting a $1.085 billion collaboration with Chugai Pharmaceutical. The company also announced successful preclinical data for oral delivery of semaglutide and initiated a Phase 1 study for RT-114, a dual agonist for obesity. Rani's CEO expressed optimism about advancing their RaniPill® platform in 2026.
Read more →RANI▼ -5.3%on this news· ran to -36% by day 3shared move
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Rani Therapeutics has appointed Jesper Høiland as Head of Strategy to enhance its corporate and pipeline strategies. Høiland, who has over 30 years of experience in the pharmaceutical industry, will focus on prioritizing internal programs and exploring new therapeutic opportunities. His expertise is expected to strengthen Rani's strategic partnerships and advance its innovative oral delivery platform.
Read more →RANIRani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Rani Therapeutics will announce its financial results for Q4 and the full year 2025 on March 26, 2026. The company will also provide a business update during a conference call and webcast. The RaniPill® capsule technology aims to replace traditional injection methods with oral dosing, showcasing Rani's commitment to innovation in drug delivery.
Read more →RANIRani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Rani Therapeutics has promoted Alireza Javadi, Ph.D., to Chief Technical Officer. His extensive experience in medical devices and life sciences is expected to enhance Rani's supply chain and manufacturing capabilities. This promotion comes as the company embarks on a Phase 1 study of RT-114 for obesity treatment, marking a pivotal moment in its growth.
Read more →RANIRani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen
Rani Therapeutics has launched a Phase 1 study for RT-114, an orally administered capsule containing the GLP-1/GLP-2 dual agonist, PG-102, aimed at treating obesity. This collaboration with ProGen involves evaluating safety and efficacy parameters that could enhance patient experience compared to traditional injection methods. Recent data showcases PG-102's potential in glucose management and weight-loss, reinforcing its promise as an innovative metabolic therapy. Both companies will jointly develop RT-114 while sharing costs and profits from commercialization.
Read more →RANIRani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics will participate in the Evercore Healthcare Conference on December 3, 2025. CEO Talat Imran and CFO Svai Sanford will present in a fireside chat format. The conference will take place in Coral Gables, FL, and a live webcast will be available for interested parties.
Read more →RANI▼ -11%on this news
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics reported its third quarter 2025 financial results, highlighting a significant collaboration with Chugai Pharmaceutical worth up to $1.085 billion. The company also completed a $60.3 million oversubscribed private placement, ensuring a cash runway into 2028. Additionally, Rani announced the appointment of two new board members and plans to initiate a Phase 1 trial for its oral obesity therapy, RT-114, by the end of 2025.
Read more →RANI▼ -12.7%on this news· ran to +43% by day 3
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
Rani Therapeutics will present preclinical data on its RaniPill® capsule at ObesityWeek 2025. The study demonstrates that oral Semaglutide (RT-116) in dogs is bioequivalent to subcutaneous injections, producing similar weight loss results. The presentation will occur on November 6, 2025, in Atlanta, Georgia.
Read more →RANI▼ -12.9%on this news
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
Rani Therapeutics has appointed Abe Bassan and Vasudev Bailey, Ph.D., to its Board of Directors, marking a significant leadership change. The company also announced the completion of a private placement expected to yield around $60.3 million. CEO Talat Imran expressed optimism about the new directors' potential contributions to Rani's clinical-stage pipeline and oral delivery platform.
Read more →RANI▼ -12.9%on this newsshared move
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Rani Therapeutics has successfully closed a $60.3 million private placement, oversubscribed and priced at-the-market under Nasdaq rules. The funding will support the company's operations into 2028, with proceeds aimed at advancing its RaniPill® platform. The placement involved participation from various institutional investors, including the company's executive chairman.
Read more →RANI▲ +248.3%on this news· ran to +413% by day 3
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Rani Therapeutics has announced a collaboration with Chugai Pharmaceutical to develop an oral delivery system for biologics, particularly targeting rare and immunologic diseases. The deal could be worth up to $1.085 billion, including upfront payments and milestone incentives. Rani also secured $60.3 million in a private placement to fund operations through 2028.
Read more →RANI▲ +248.3%on this news· ran to +413% by day 3shared move
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Rani Therapeutics has announced an oversubscribed private placement that secured approximately $60.3 million in gross proceeds. The investment was led by Samsara BioCapital and included contributions from several notable investors. The funds will support the advancement of Rani’s innovative RaniPill® platform and are expected to sustain operational capabilities until 2028. This financing strengthens Rani's financial position, allowing for further development in collaboration with Chugai Pharmaceuticals.
Read more →RANIRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclin
Rani Therapeutics announced its financial results for Q2 2025, showcasing a strategic collaboration with Chugai for two undisclosed molecules. The company presented promising preclinical data for its oral bispecific GLP-1/GLP-2 receptor agonist, RT-114, which demonstrated bioequivalence to subcutaneous injections in canines. Additionally, Rani plans to initiate a Phase 1 trial for RT-114 in the latter half of 2025. Financially, the company reported a net loss of $11.2 million and a significant drop in cash reserves compared to the previous year.
Read more →RANI▼ -38.9%on this news
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Rani Therapeutics Holdings, Inc. has announced a registered direct offering of $3.0 million, selling 4,354,000 shares of Class A common stock at $0.40 per share. The offering, facilitated by Maxim Group LLC, is expected to close on July 16, 2025, pending customary closing conditions. This funding will support Rani's development of its proprietary oral delivery technologies.
Read more →RANI▲ +8.4%on this news· ran to -35% by day 3shared move
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rani Therapeutics announced a late-breaking presentation at ENDO 2025, showcasing preclinical data on its RaniPill capsule. The study demonstrated bioequivalence of a bispecific GLP-1/GLP-2 receptor agonist delivered orally compared to subcutaneous injection in canines. This advancement highlights Rani's commitment to developing innovative oral delivery systems for biologics.
Read more →RANI▲ +9.3%on this news
Rani Therapeutics Announces Research Agreement with Chugai
Rani Therapeutics has entered a research agreement with Chugai Pharmaceutical to evaluate the feasibility of applying its oral delivery technology to Chugai's antibodies. The RaniPill delivery system has demonstrated comparable bioavailability to subcutaneous delivery for the studied molecules. This collaboration aims to leverage both companies' strengths in drug development.
Read more →RANI▼ -21.4%on this news
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), deliv
Rani Therapeutics Holdings, Inc. announced its financial results for Q1 2025 and highlighted significant advancements in its product pipeline, particularly with RT-114, a bispecific GLP-1/GLP-2 receptor agonist. Key preclinical data showcased that the RaniPill capsule can deliver RT-114 orally with bioequivalence to existing subcutaneous methods. Furthermore, a Phase 1 study for RT-114 is anticipated to start in mid-2025. The financial performance indicated a decrease in cash reserves alongside a reduction in net losses compared to the previous year.
Read more →RANI▼ -7.4%on this news
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delive
Rani Therapeutics reported its financial results for Q4 and the full year 2024, showing promising preclinical data for its oral delivery system, the RaniPill. Notably, data revealed that RT-114, a dual agonist for obesity treatment, demonstrated bioequivalence compared to subcutaneous administration. The company also announced plans to begin a Phase 1 study for RT-114 in mid-2025. However, Rani reported a significant net loss of $56.6 million for 2024 and an impairment loss on its property and equipment.
Read more →RANIRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill Capsule, to Subcutaneously Administered PG-102
Rani Therapeutics announced promising preclinical data revealing that RT-114, an orally administered GLP-1/GLP-2 dual agonist, exhibits bioequivalence to subcutaneously administered PG-102. The results showed a relative bioavailability of 111% and comparable weight loss outcomes, with RT-114 demonstrating less variability in weight loss among subjects. The company plans to initiate a Phase 1 clinical trial for RT-114 in mid-2025, aiming to address the need for effective oral obesity treatments.
Read more →RANIRani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Rani Therapeutics Holdings, Inc. plans to report its financial results for the fourth quarter and full year ended December 31, 2024, on March 31, 2025. The management team will provide a business update during a conference call and webcast scheduled for 4:30 p.m. ET. The RaniPill® capsule, a proprietary platform technology, is designed to facilitate oral delivery of biologics and drugs, with prior successful clinical evaluations indicating its potential.
Read more →RANI▲ +5.1%on this news· ran to +20% by day 1
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC
Rani Therapeutics announced promising preclinical results for its RaniPill® HC (RT-116), demonstrating successful oral delivery of semaglutide, a GLP-1 agonist. The study showed that oral administration had comparable bioavailability and weight loss effects to traditional subcutaneous methods. This advancement could provide a more convenient, once-weekly treatment option for patients struggling with obesity. The company plans to initiate a Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist, in 2025.
Read more →RANIRani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - A
Rani Therapeutics has reported its financial results for Q3 2024, highlighting the completion of two equity offerings that raised approximately $20 million, allowing for an extended cash runway into Q3 2025. The company announced encouraging preclinical pharmacokinetic data that supports the potential of the RaniPill platform for oral drug delivery in the obesity therapeutics market. They are also set to initiate a Phase 1 trial for RT-114, a dual agonist for obesity treatment, expected in 2025. Despite a reported net loss of $12.7 million, progress in research and development appears promising.
Read more →RANIRani Therapeutics to Participate in Upcoming Investor Conferences
Rani Therapeutics Holdings, Inc. has announced its management team's participation in three upcoming investor conferences. These events include the UBS Global Healthcare Conference on November 14, the Stifel Healthcare Conference on November 18, and the Evercore ISI HealthCONx Conference on December 4. The company aims to enhance its visibility in the biotherapeutics sector through presentations and 1x1 meetings at these conferences. Rani Therapeutics is known for its proprietary RaniPill® capsule technology, designed to deliver biologics orally, potentially replacing traditional injection methods.
Read more →RANIRani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
Rani Therapeutics has announced new pharmacokinetic data supporting its RaniPill platform for oral delivery of incretin triagonists, which are seen as a promising approach to obesity treatment. The study showed that transenteric delivery resulted in rapid weight loss and bioavailability similar to that of subcutaneous injections. A Phase 1 clinical trial for RT-114, an oral GLP-1/GLP-2 dual agonist, is anticipated to begin in 2025. The findings validate the platform's potential to provide painless alternatives to traditional injection methods for multiple obesity treatments.
Read more →RANI▼ -33.3%on this newsshared move
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
Rani Therapeutics Holdings, Inc. has announced a registered direct offering to raise approximately $10.0 million by selling 3,000,000 shares of Class A common stock and pre-funded warrants. In conjunction with this offering, the company will cancel outstanding Series A common warrants previously issued. The placement is expected to close on or about October 16, 2024, and is facilitated by Maxim Group LLC. This transaction aims to bolster Rani Therapeutics' financial position as it continues its mission in biotherapeutics.
Read more →RANIRani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
Rani Therapeutics Holdings, Inc. will participate in the 2024 Maxim Healthcare Virtual Summit, with CEO Talat Imran and CFO Svai Sanford scheduled for a fireside chat. The event will take place on October 17, 2024, focusing on advancements in the oral delivery of biologics and drugs. Rani's RaniPill® capsule technology aims to replace traditional injection methods. This participation marks an opportunity for Rani to showcase its innovations and engage with interested parties.
Read more →RANI▼ -7.5%on this news· ran to -18% by day 3
Rani Therapeutics to Participate in September Investor Conferences
Rani Therapeutics Holdings, Inc. will participate in two significant investor conferences in September 2024. The H.C. Wainwright 26th Annual Global Investment Conference is scheduled for September 10, followed by the 2024 Cantor Global Healthcare Conference on September 18. CEO Talat Imran will present at both events, focusing on the company's innovative oral delivery technologies in biotherapeutics. Interested investors can access live webcasts of the presentations through the company’s website.
Read more →RANIRani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics reported its Q2 2024 financial results, highlighting a transformative partnership with ProGen to co-develop RT-114, an oral dual agonist for obesity. The anticipated Phase 1 study for RT-114 is set to begin in 2025. Rani's recent equity offering raised approximately $10 million, although net losses have increased compared to the previous year. Rani also presented promising clinical data on its oral delivery system for a biosimilar treatment.
Read more →RANIRani Therapeutics to Participate in August Investor Conferences
Rani Therapeutics Holdings, Inc. will participate in two investor conferences in August 2024, including the BTIG Virtual Biotechnology Conference and the Canaccord 44th Annual Growth Conference. The CEO, Talat Imran, will present at the Canaccord conference. Rani specializes in the oral delivery of biologics and has developed the RaniPill® capsule aimed at replacing traditional injection methods. This engagement may help the company to strengthen investor relations and broaden its market presence.
Read more →RANIRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
Rani Therapeutics Holdings, Inc. announced the pricing of a $10 million registered direct offering, which involves the sale of 2,800,000 shares of its Class A common stock along with pre-funded warrants and Series A and B common warrants. The offering is expected to close on July 23, 2024, following successful completion of customary closing conditions. Maxim Group LLC is serving as the sole placement agent for this transaction, which aims to bolster Rani's efforts in oral delivery technologies for biologics and drugs.
Read more →RANIRani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
Rani Therapeutics has partnered with ProGen to co-develop RT-114, an oral treatment for obesity that utilizes ProGen's GLP-1/GLP-2 dual agonist, PG-102, in Rani's proprietary RaniPill® capsule. The partnership entails a 50/50 cost and revenue share, with Rani leading operations in North America and Europe, while ProGen focuses on other regions. The project aims to provide a convenient alternative to injections, potentially improving patient adherence and therapeutic outcomes. Initial clinical activities are expected to begin in 2025.
Read more →RANIThis presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 19
Rani Therapeutics has announced a collaboration with ProGen Co., Ltd. to advance their development of oral biologics, specifically targeting the obesity market. Their strategic vision includes optimizing drug delivery and enhancing patient compliance. The partnership is focused on developing RaniPill technology for improved therapeutic efficacy, but the project faces inherent risks associated with clinical trials and regulatory approval processes. Both companies highlight the potential of their collaboration to innovate treatments for chronic diseases.
Read more →RANI▼ -5.4%on this news
Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics Holdings, Inc. will participate in two investor conferences in May 2024, including the H.C. Wainwright 2nd Annual BioConnect Conference and the UBS Spring Biotech Conference. CEO Talat Imran will present at the BioConnect Conference in a fireside chat format, and there will be one-on-one meetings at the UBS Conference. These events are significant for Rani as they provide opportunities to engage with potential investors and showcase their RaniPill technology, which allows for the oral delivery of biologics and drugs.
Read more →RANI▼ -5.2%on this news· ran to -19% by day 3shared move
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024
Rani Therapeutics will present clinical and preclinical data on its RaniPill capsule, which delivers an ustekinumab biosimilar, at Digestive Disease Week 2024. The sessions include a late-breaking oral presentation on the safety and bioavailability of the drug in humans, and a poster session on the drug's efficacy in canines. This event is a significant opportunity for Rani Therapeutics to demonstrate its innovative technology and findings to a large audience of medical professionals.
Read more →RANI▲ +5.7%on this newsshared move
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phas
Rani Therapeutics reported its financial results for the first quarter of 2024, highlighting positive topline results from its Phase 1 study of oral anti-interleukin antibody RT-111. The company announced plans for a Phase 2 clinical trial for RT-102 targeting osteoporosis and anticipated readiness of RaniPill HC for Phase 1 trials later in 2024. Financial data showed a decrease in cash reserves and a net loss, yet improvements in expenses were noted. Overall, these developments underscore Rani's ongoing progress in their clinical endeavors despite facing financial hurdles.
Read more →RANIRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Ann
Rani Therapeutics announced its financial results for Q4 and FY 2023, showcasing positive topline results from its Phase 1 study of RT-111. The study indicated high bioavailability and tolerability for the oral anti-interleukin antibody. Rani's cash reserves have been extended into 2025, but the company reported a net loss of $67.9 million for the year. Additionally, some of its development programs, such as RT-101, have been discontinued, raising concerns about future growth and advancements.
Read more →RANI▲ +6.3%on this newsshared move
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Rani Therapeutics Holdings, Inc. will release its financial results for Q4 and the full year of 2023 on March 20, 2024. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Rani specializes in the oral delivery of biologics and has developed the RaniPill® capsule linked to advancements in drug administration technology.
Read more →RANI▲ +5.7%on this news
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious
Rani Therapeutics announced positive topline results from its Phase 1 study of RT-111, an oral anti-interleukin 12/23 antibody. The study showed that RT-111 achieved high bioavailability and was well-tolerated among participants, with no serious adverse events reported. RT-111 is noted as the first oral monoclonal antibody to reach significant bioavailability in humans, which could present a new alternative for treating autoimmune conditions such as psoriasis. The success of this study marks an important milestone in Rani's development of oral biologics.
Read more →RANIRani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamlin
Rani Therapeutics reported its third quarter 2023 financial results, highlighting a cash runway extended into 2025 and strategic program prioritization. The company initiated a Phase 1 trial of RT-111 and has plans for a Phase 2 trial of RT-102 by year-end 2023. Despite positive developments, Rani also announced a 25% workforce reduction and discontinued the development of RT-101 amidst increasing net losses.
Read more →RANIRani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Plat
Rani Therapeutics has announced a strategic program prioritization alongside a manufacturing expansion to foster near-term value and long-term growth of its RaniPill technology. Significant actions include a focus on key programs RT-102 and RT-111, while also pausing RT-105 and RT-110, and the discontinuation of RT-101. Additionally, the company plans to reduce its workforce by 25% to align operational costs with these strategic moves. Rani's financial outlook shows an expected cash runway extending into 2025, supporting further development of key projects.
Read more →RANIThe RaniPill Capsule, Rani Therapeutics' Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Daily administration for 60 days was well-tolerated with no treatment-related adver
Rani Therapeutics announced positive results from a 60-day GLP safety study of its RaniPill Capsule, which indicated it was well-tolerated with no treatment-related adverse events in healthy animals. This encouraging data supports the safety profile of the RaniPill platform, paving the way for longer-term clinical trials, including a planned Phase II study for RT-102 in osteoporosis. The RaniPill platform aims to provide oral delivery options for biologics typically administered via injections, enhancing patient comfort and compliance.
Read more →RANIRani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies - Two preclinical studies of RaniPill HC achieved 18/20 successful drug delivery of orally administered teriparatide resul
Rani Therapeutics announced successful results from two preclinical studies of the RaniPill HC, achieving an impressive 90% success rate in delivering teriparatide. This high-capacity pill can potentially deliver a greater payload, enabling the treatment of many more drug candidates. Moving forward, Rani plans to continue preclinical testing while anticipating a Phase 1 clinical trial for the adalimumab RT-105. The development reflects a significant step towards providing patients an alternative to painful injections.
Read more →RANIRani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment o
Rani Therapeutics reported its second quarter financial results, highlighting an expansion of its partnership with Celltrion for the development of RT-105. The company appointed Kate McKinley as Chief Business Officer, enhancing its executive team. Multiple abstracts were presented at the Endocrine Society Annual Conference, including a winning presentation on RT-102. Looking forward, Rani aims to initiate Phase 2 studies for RT-102 and Phase 1 studies for RT-111 in the second half of 2023, despite reporting a net loss of $18.7 million for the quarter.
Read more →RANIRani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from th
Rani Therapeutics has reported its financial results for the fourth quarter and full year of 2022, showcasing transformative developments including positive topline results for RT-102 and a partnership with Celltrion for RT-111. The company anticipates initiating the first Phase 2 clinical study of RT-102 in the second half of 2023, along with multiple Phase 1 studies for additional pipeline assets. Despite a decrease in cash reserves and an increased net loss, Rani remains focused on advancing its oral delivery technology for biologics and drugs.
Read more →RANI▲ +8.1%on this news
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticip
Rani Therapeutics announced a positive pre-IND meeting with the FDA regarding the development of RT-102, a biological treatment for osteoporosis. The company received encouraging feedback indicating that the 505(b)(2) pathway is appropriate for RT-102's U.S. development. Rani also revealed plans to initiate a Phase 2 clinical trial for RT-102 in the latter half of 2023, along with three additional Phase 1 studies for other candidates. Additionally, Rani reported that its Phase 1 study of RT-102 achieved all endpoints and demonstrated good tolerability.
Read more →RANIRani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well toler
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill GO deli
Read more →RANIRani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO
Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potenti
Read more →RANI▼ -10%on this news
Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update - Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treat
Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update - Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn s
Read more →RANIRani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional
Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund
Read more →RANIRani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis - Unveiled the high-capacity RaniPill HC, capable
Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis - Unveiled the high-capacity RaniPill HC, capable of delivering payloads of up to - Strengthened Board wi
Read more →RANIRani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-ca
Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - Unveiled the high-capacity RaniPill HC, capable of delivering payloads of up to
Read more →RANI▼ -8.5%on this news· ran to +25% by day 3
Rani Therapeutics Unveils High-Capacity RaniPill Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results - Preclinical data demonstrates new RaniPill HC (High Capacity) delivered 50
Rani Therapeutics Unveils High-Capacity Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results - Preclinical data demonstrates new RaniPill HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill capsule - payload has the pot
Read more →RANIRani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update
Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update SAN JOSE, Calif., November 15, 2021 Rani Therapeutics Holdings, Inc. ( Rani Therapeutics or Rani ) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of
Read more →RANIThis presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith
Redefining Oral Biologics September This presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith beliefs and assumptio
Read more →RANI▲ +6.2%on this news
Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update - IPO in July 2021 raised $84.3 million in gross proceeds - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership
Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update - IPO in July 2021 raised $84.3 million in gross proceeds - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors appointm
Read more →Competitive Position
How RANI ranks across every disease it competes inCompetitive Position is a premium feature
See how RANI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial